{"id":55430,"date":"2026-04-25T08:12:37","date_gmt":"2026-04-25T08:12:37","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/55430\/"},"modified":"2026-04-25T08:12:37","modified_gmt":"2026-04-25T08:12:37","slug":"roche-ms-pill-cuts-relapses-but-safety-questions-persist","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/55430\/","title":{"rendered":"Roche MS Pill Cuts Relapses But Safety Questions Persist"},"content":{"rendered":"<p class=\"ArticleBodyText_articleBodyContent__17wqE typography_articleBody___5jDr\" data-component=\"paragraph\"><a href=\"https:\/\/www.bloomberg.com\/quote\/ROP:SW\" target=\"_blank\" rel=\"noopener nofollow\" class=\"media-ui-Link_link-tVkXhPLPofs-\" data-component=\"link\">Roche Holding AG<\/a>\u2019s experimental multiple sclerosis pill roughly halved the number of disease relapses in two key late-stage studies, but more patients died while on the medicine, perpetuating safety concerns. <\/p>\n<p class=\"ArticleBodyText_articleBodyContent__17wqE typography_articleBody___5jDr\" data-component=\"paragraph\">Patients taking fenebrutinib suffered a relapse roughly every 17 years compared to an older treatment, according to data presented at the American Academy of Neurology annual meeting in Chicago. Seven volunteers died during the study\u2019s reporting period and another one later, Roche said. By comparison, there was one death in the trial\u2019s control arm.<\/p>\n","protected":false},"excerpt":{"rendered":"Roche Holding AG\u2019s experimental multiple sclerosis pill roughly halved the number of disease relapses in two key late-stage&hellip;\n","protected":false},"author":2,"featured_media":55431,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[124],"tags":[31079,2009,77,7983,4397,167,10622,3310,134,473,3198,17],"class_list":["post-55430","post","type-post","status-publish","format-standard","has-post-thumbnail","category-roche","tag-american-academy-of-castle-p","tag-banking","tag-basel","tag-chicago","tag-drugs","tag-finance","tag-industries","tag-regulation","tag-roche","tag-roche-holding-ag","tag-seven","tag-switzerland"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/116464343229128778","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/55430","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=55430"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/55430\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/55431"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=55430"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=55430"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=55430"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}